– USA, CA – Avellino Lab USA, Inc., a global leader in molecular diagnostics, today announced the appointment of Virginia Gambale to its Board of Directors.
“We are thrilled to welcome Virginia to Avellino. Her expertise in both technology and finance will be invaluable as we continue to leverage the power and promise of genetic science and data technology to support our mission to improve human health,” said CEO, Jon Robson.
About Virginia Gambale
Virginia Gambale is currently Managing Partner of Azimuth Partners LLC, which is focused on the use of disruptive technologies to assist in transforming or facilitating growth in both middle market and large corporations. She has served on more than 20 public and private boards as Chair, Lead Director, and Committee Chair roles, including at JetBlue, Motive, Piper Jaffray, Workbrain, Synchronoss Technologies, and IQ Financial.
Ms. Gambale currently serves on several boards, including as Chair of the Board, Director, Chair of Nominating and Corporate Governance, and Audit Committee member at Nutanix; JAMF Audit Committee Member; FD Technologies as their Chair of Nominating and Governance and Audit Committee member; and Virtu Financial as a member of their Audit and Chair of Risk Committee. She is also an Executive Advisor for AttackIQ, a leading cybersecurity optimization platform, and private company director for Banking 10X.
“We are in an exceptional time as the scientific community is making novel discoveries on a continual basis, not to mention advances in areas such as AI and machine learning that are accelerating the pace of this scientific knowledge,” commented Virginia Gambale. “It is a privilege to join a leading biotechnology firm that is committed to applying the latest scientific and technological knowledge to help improve health and further unlock the mysteries of the human genome. I look forward to applying my skills and expertise toward their mission to advance how we both diagnose and treat disease.”
Ms. Gambale has held significant senior management positions, including as CIO and Managing Director at firms including Merrill Lynch, Bankers Trust, Deutsche Bank, and Marsh McLennan. Additionally, she was the Head of Deutsche Bank Strategic Ventures and subsequently a General Partner at Deutsche Bank Capital and ABS Ventures until founding Azimuth Partners in 2003.
A former concert pianist, Ms. Gambale was the Board President of the Newport Music Festival from 2014 to 2019. She is also an adjunct faculty member at Columbia University and Mentor for Columbia University’s Masters in Technology Leadership program. In addition, she is a frequent lecturer and keynote speaker on the strategic use of emerging technologies and cybersecurity and was one of the first National Association of Corporate Directors Fellows.
Ms. Gambale has a B.S. degree in Mathematics and Computer Science from the New York Institute of Technology.
About Avellino
Avellino Lab USA, Inc. is a global leader in molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. The company also developed the Avellino SARS-CoV-2 RT-PCR diagnostic test to aid in COVID-19 pandemic testing efforts in the U.S. The first private company in the U.S. to receive EUA for its COVID-19 test, Avellino has performed more than three million COVID-19-related tests to date. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.
For more information: https://www.avellino.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
